Stock Market & Financial Investment News

News For ALXA From The Last 14 Days Check below for free stories on ALXA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 14, 2013 16:13 EDT ALXA Alexza Pharmaceuticals reports Q1 EPS ($1.31), consensus (45c) Subscribe for More Information May 8, 2013 12:39 EDT ALXA Options with increasing implied volatility: ALXA FIO EBIX VMED HNZ Subscribe for More Information 12:00 EDT ALXA Alexza Pharmaceuticals rises 23.7% Alexza Pharmaceuticals is up 23.7%, or $1.03, to $5.37 10:26 EDT ALXA Alexza deal with Teva could be worth $12 per share or more, says Roth Capital Subscribe for More Information 10:01 EDT ALXA Alexza Pharmaceuticals rises 32.7% Subscribe for More Information 09:06 EDT ALXA Alexza Pharmaceuticals to host conference call Subscribe for More Information 08:33 EDT ALXA Teva, Alexza announce Teva's license to market Adasuve in the U.S. Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical (TEVA), and Alexza Pharmaceuticals (ALXA) announced that the companies have entered into an exclusive U.S. license and supply agreement for Adasuve inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for Adasuve, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of Adasuve for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying Adasuve to Teva for commercial sales and clinical trials. Under the terms of the license and supply agreement, Alexza will receive an upfront cash payment of $40M and is eligible to receive up to $195M in additional milestone payments, based upon successful completion of the ADASUVE post-approval studies in the U.S. and achieving net sales targets. In addition, Teva will make tiered, royalty payments based on net commercial sales of Adasuve. 08:25 EDT ALXA Alexza Pharmaceuticals trading halted, pending news Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.